|
|
|
| Plasma interleukin-10 and 25(OH) Vitamin D in patients with lung cancer and its clinical value |
1.Department of Clinical Laboratory Medicine, Dongyang People’s Hospital, Jinhua, 322100; 2. School of Laboratory Medicine, Wenzhou Medical University, Wenzhou, 325035
|
|
| Cite this article: |
|
WANG Maofeng1,YING Jun2,JIANG Xinliang1, et al. Plasma interleukin-10 and 25(OH) Vitamin D in patients with lung cancer and its clinical value[J]. JOURNAL OF WEZHOU MEDICAL UNIVERSITY, 2014, 44(11): 829-.
|
|
|
Abstract Objective: To investigate plasma interleukin-10 (IL-10) and 25 (OH) vitamin D in patients with lung cancer and its clinical value. Methods: From March 2012 to January 2013, 78 cases newly admitted patients with lung cancer in our hospital were enrolled, including 40 cases of adenocarcinoma, 28 cases squamous cell carcinoma, 10 cases of small cell carcinoma, select age and sex matched 50 healthy volunteers as a control group. Analysis of 25 (OH) vitamin D and IL-10 in the differences among the groups and their correlation. Results: Lung cancer patients plasma 25 (OH) vitamin D concentration were (24.5±6.8) ng/mL, lower than the healthy control group 35.1±8.7 ng/mL, lung cancer patients plasma IL-10 concentrations were 1 031 (805~1 243) ng/L, higher than the healthy control group, the difference was statistically significant (P<0.05); lung adenocarcinoma patients plasma 25 (OH) vitamin D concentrations was not statistically significant difference in patients with squamous cell carcinoma of lung (P>0.05), lung adenocarcinoma patients plasma concentrations of IL-10 were 1 255 (1 050~1 440) ng/L, higher than that in patients with squamous cell carcinoma of lung, the difference was statistically significant (P<0.05), there is no correlation of plasma IL-10 and 25 (OH) vitamin D in patients with lung cancer (r=-0.011, P>0.05). Conclusion: Plasma 25 (OH) vitamin D and IL-10 concentration anomalies in patients with lung cancer, we suggesting that plasma 25 (OH) vitamin D and IL-10 concentration detection are helpful for monitoring the treatment and prognosis of patients with lung cancer.
|
|
Received: 17 January 2014
|
| |
|
|
|
|
|
|
2014, Vol. 44 
